NATF completed this year a pivotal project, the Atrial Fibrillation Action Initiative. Led by Board Member Christian T. Ruff, MD, MPH, the Atrial Fibrillation Action Initiative serves the patient and healthcare provider communities with updated and factual information on how best to prevent stroke from atrial fibrillation (AF)... (read more)
Scientific and Clinical Developments and their Impact on the Understanding of the Pathogenesis of Thrombosis and its Management
Loyala University Medical Center
Auditorium CTRE Building
October 28, 2016
Under the Auspices of International Union of Angiology and The North American Thrombosis Forum
A Century of Scientific Fascination and Clinical Implementation
In conjunction with XXVII World Congress of the International Union of Angiology and 15th Congress of the
French Society of Vascular Medicine
Friday, October 7, 2016
Free CME Summit
Saturday, September 17, 2016
Boston Marriott Long Wharf
A distinguished panel of national cardiovascular medicine experts, including Harvard’s Deepak Bhatt, MD and Paul Ridker, MD, will discuss practical, patient-centric approaches to LDL lowering, with a focus on the case-based application of multimodal approaches to LDL management across the hypercholesterolemic morbidity continuum, including diabetes, statin intolerance, and poorly responsive patients with elevated LDL.
2016 THROMBOSIS SUMMIT
Saturday, October 1
7:00 AM - 12:00 PM
Fairmont Copley Plaza Hotel, Boston, MA
This special half-day program is designed for physicians, pharmacists, nurses, nurse practitioners, physician assistants,and allied health professionals. Patients, family members and caregivers are also encouraged to attend.
Earn up to 3.5 CME credits for attendance
Experts in the field of Thrombosis Medicine will share updates from breakthrough research that has been completed over the last year on blood clots including heart attack, stroke as a result of atrial fibrillation, pulmonary embolism, and deep vein thrombosis.
Three patient survivors of major thrombotic events will provide their perspective, recounting their experience from initial symptoms and diagnosis through treatment to recovery. Reserve your seat now!
The date of the Summit meeting is scheduled to coincide with the
10th ANNUAL NORTH AMERICAN DAWN AC USER GROUP
Friday, September 30
Brigham and Women's Hospital
To register or find out more
about the program, please contact
Melissa Blanchard at Melissa@4s-dawn.com
Space Still Available!
5th Regional AC Forum Bootcamp
October 6-7, 2016
Hotel Albuquerque at Old Town
This compact 2-day meeting provides a comprehensive curriculum that covers the essential aspects of anticoagulation,disease state, and drug management. Engaging discussion around quality improvement, new agents and special situations will benefit all practicioners and daily "chalk talks" will allow for attendee participation to shape the topics.
For more information or to register visit
DVT/PE TREATMENT OPTIONS
How do healthcare providers decide which treatments are the best option for their patients? Read this article to find out more about DVT/PE treatment goals, options, risks, and decision-making.
For many years, Warfarin was the only oral anticoagulant commonly used to treat blood clots. In the past five years, the FDA has approved four new oral anticoagulants for the treatment of DVT, PE, and SPAF. Find out the differences between the five FDA-approved oral anticoagulants. View the Chart.
ATRIAL FIBRILLATION ACTION INITIATIVE - NOW PUBLISHED
The American Journal of Medicine published the NATF Atrial Fibrillation Action Initiative consensus document in April 2016. This document presents usable recommendations on stroke prevention, bleeding risk assessment, and anticoagulation management based off clinical trial data and guideline updates for Afib. Please visit the AFib section of our website to learn more.